InspireMD and NAMSA Unite for CGUARDIANS II Clinical Trial
In a significant step forward for the medical technology field, InspireMD and NAMSA have joined forces to conduct the pivotal CGUARDIANS II study, focusing on the CGuard Prime™ 80 cm carotid stent system designed for Transcarotid Artery Revascularization (TCAR) procedures. This collaboration aims at improving the prevention of stroke associated with carotid artery stenosis, a condition that affects many individuals.
Marvin Slosman, the Chief Executive Officer of InspireMD, shared insights into the potential of this partnership. He pointed out that more than 30,000 TCAR procedures are successfully performed annually in the United States, indicating a rapidly growing demand in this area. “This procedure represents a significant market opportunity and is crucial for our mission to cater to a diverse patient population,” he emphasized. By collaborating with NAMSA, InspireMD can capitalize on their extensive clinical and regulatory expertise to ensure the trial’s success.
What the CGUARDIANS II Trial Entails
The CGUARDIANS II study is a carefully crafted, multi-center, single-arm trial aiming to enroll at least 50 evaluable patients. Its principal goal is to assess the success rates and technical efficacy of the CGuard Prime device when partnered with an FDA-cleared neuro-protection system. This study is vital for evaluating how well the device performs in patients deemed at high risk for complications from carotid endarterectomy.
Goals of the Clinical Study
The overall aim of CGUARDIANS II is to gather data concerning the acute device success and technical performance of the CGuard Prime system. By aligning with an FDA-authorized embolic protection device, the study will provide essential insights into the safety and effectiveness of TCAR procedures.
Expert Insights on the Partnership
Dr. Adam Saltman, NAMSA’s Chief Medical Officer, expressed his enthusiasm: “The CGUARDIANS II study is exemplary of how NAMSA collaborates with innovative companies like InspireMD. Our seasoned experience in carotid disease and stenting methodologies informs how we conduct this vital research.” With over four decades of involvement in clinical investigations, NAMSA is optimistic about the collaborative efforts to advance treatment options.
InspireMD’s Innovation in Stroke Prevention
InspireMD’s commitment to stroke prevention includes the use of its proprietary MicroNet® technology. This approach aims to set new standards in carotid stenting, boasting not only acute success but also long-term outcomes devoid of strokes. As the company continues on its innovative path, they remain focused on delivering solutions that improve patient care.
Stay Updated on the Clinical Developments
Communication with investors and interested parties remains a priority for InspireMD. Regular updates about the trial and other key developments are posted on their official website. As they progress with CGUARDIANS II, stakeholders can access detailed information regarding the study’s advancements and implications for future medical practices.
Ongoing Support from the Medical Community
As the CGUARDIANS II clinical trial moves forward, the medical community holds high expectations for the outcomes it promises. The collaboration between InspireMD and NAMSA not only represents a critical step in medical research but also exemplifies how cooperation in the industry can lead to enhanced techniques and better patient outcomes.
Frequently Asked Questions
What is the purpose of the CGUARDIANS II trial?
The CGUARDIANS II trial aims to evaluate the safety and efficacy of the CGuard Prime carotid stent system in TCAR procedures for patients at high risk of complications.
How many patients is the CGUARDIANS II study looking to enroll?
The study aims to enroll at least 50 evaluable patients to assess the device's success and technical performance.
Who are the key players in this partnership?
The major collaborators are InspireMD, Inc. and NAMSA, both of which have significant expertise in medical devices and clinical trials.
What technology is InspireMD utilizing in this trial?
InspireMD is utilizing its MicroNet® technology, which aims to enhance the efficacy of carotid stenting while minimizing the risk of strokes.
How will the results impact future medical practices?
The results from CGUARDIANS II could lead to improved treatment options for carotid artery stenosis, influencing both clinical practices and patient outcomes in stroke prevention.
